1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • May 2014
  • 381 pages
  • GlobalData
Report ID: 2386264

Summary

Table of Contents

PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

Summary

Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing a direct-acting antiviral (DAA), such as Gilead's Sovaldi (sofosbuvir) or Janssen's Olysio (simeprevir), along with pegylated interferon (e.g., Roche’s Pegasys and Merck’s PegIntron) and/or ribavirin (e.g., Roche’s Copegus and Merck’s Rebetol) are used to treat HCV infections. Sovaldi and Olysio have largely replaced first-generation NS3/4A protease inhibitors, such as Vertex's Incivek (telaprevir) and Merck's Victrelis (boceprevir) due to their increased tolerability, efficacy, and shorter treatment duration. The entrance of next-generation , all-oral HCV therapies is expected to fundamentally alter the HCV treatment algorithm.

Highlights

Key Questions Answered

- How quickly, and to what extent, will interferon-sparing and all-oral regimens replace Incivek and Victrelis in the treatment algorithm?
- What role, if any, will interferon-based therapies have in the HCV treatment landscape over the next decade?
- Which novel HCV therapies will face adoption challenges in the market? What is the projected uptake of new drugs, such as Merck’s MK-5172/MK-8742, over the forecast period?
- Will the reduced pill burden and increased convenience of fixed-dose, all-oral combination therapies lead to their widespread uptake?
- How will pricing influence the use of next-generation DAAs?
- Which HCV regimen(s) in development are physicians most excited about?

Key Findings

- Patient awareness is anticipated to increase in response to government education and screening initiatives.
- Interferon use is predicted to drastically decrease over the next 10 years.
- The launch of next-generation, all-oral DAA regimens is expected to streamline the HCV treatment algorithm.
- The approval of more-tolerable HCV therapies is likely to result in patients deciding to undergo treatment (i.e., decrease in the warehouse effect).
- Fixed-dose combination therapies are expected to seize market share due to their reduced pill burden and convenience.

Scope

- Overview of hepatitis C virus (HCV), including epidemiology, etiology, general symptoms from infection, and national vaccination recommendations and guidelines.
- Annualized HCV therapeutics market revenue, annual cost of therapy, and treatment usage pattern data from 2012 and forecast for 10 years to 2022.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HCV market.
- Pipeline analysis: comprehensive data split across different phases, and emerging trends, specifically interferon-free therapies and fixed-dose combinations.
- Analysis of the current and future market competition in the global HCV therapeutics market. Insightful review of the key industry and governmental drivers, restraints and challenges.
- Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global HCV therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HCV market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global HCV therapeutics market from 2012-2022.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Amrita helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Hepatitis C Therapeutics in Asia-Pacific Markets to 2023 - Presence of Outstanding Direct-Acting Antivirals and Late-Stage Pipeline to Transform the Clinical and Commercial Landscape

  • $ 4995
  • Industry report
  • August 2017
  • by GBI Research

Hepatitis C Therapeutics in Asia-Pacific Markets to 2023 - Presence of Outstanding Direct-Acting Antivirals and Late-Stage Pipeline to Transform the Clinical and Commercial Landscape Summary Recent years ...

Antiviral Drugs Market: Global Industry Analysis, Trends, Market Size & Forecasts to 2023

  • $ 4795
  • Industry report
  • September 2017
  • by Infinium

The report on global Antiviral Drugs market provides qualitative and quantitative analysis for the period of 2017 to 2023. The report predicts the global Antiviral Drugs market to grow with a CAGR between ...

Chronic Liver Disease Global Clinical Trials Review, H1, 2017

  • $ 2500
  • Industry report
  • June 2017
  • by GlobalData

Chronic Liver Disease Global Clinical Trials Review, H1, 2017 Summary GlobalData’s clinical trial report, “Chronic Liver Disease Global Clinical Trials Review, H1, 2017" provides an overview of Chronic ...


Download Unlimited Documents from Trusted Public Sources

Health Services Industry in the UK

  • September 2017
    19 pages
  • Cardiology  

    Neurology  

    Hospital  

  • United Kingdom  

    Europe  

View report >

Infectious Disease Statistics and Vaccine Market in Haiti

  • September 2017
    9 pages
  • Infectious Dise...  

    Vaccine  

    Healthcare  

  • Haiti  

View report >

Infectious Disease Statistics and Vaccine Market in the Netherlands

  • September 2017
    157 pages
  • Infectious Dise...  

    Vaccine  

    Healthcare  

  • Netherlands  

    Europe  

View report >

Related Market Segments :

Antiviral
Hepatitis

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.